

Alectinib ALUR

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Less serious and disabling adverse events observed

Other adjustments



Alectinib ALUR

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: As monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib

Experimental Arm: Alectinib

Control Arm: Chemotherapy (pemetrexed or docetaxel)



